百利天恒(688506.SH)：BL-M08D1(ADC)临床试验申请获得批准

智通财经2024-11-28

智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M08D1(ADC)的药物临床试验获得批准。BL-M08D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物，其适应症为复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2486396776?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-28 18:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486396776","market":"hk","top_or_hot":-1,"title":"百利天恒(688506.SH)：BL-M08D1(ADC)临床试验申请获得批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M08D1(ADC)的药物临床试验获得批准。BL-M08D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物，其适应症为复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1217375.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒(688506.SH)：BL-M08D1(ADC)临床试验申请获得批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒(688506.SH)：BL-M08D1(ADC)临床试验申请获得批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-28 18:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1217375.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M08D1(ADC)的药物临床试验获得批准。BL-M08D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物，其适应症为复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1217375.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1217375.html","article_id":"2486396776","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486396776","pubTimestamp":1732788963,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M08D1(ADC)的药物临床试验获得批准。BL-M08D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物，其适应症为复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688506":"百利天恒","BK0239":"医药制造","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BK4231":"零售房地产信托","BK1141":"生命科学工具和服务","BL":"Blackline Inc.","BK1576":"医药外包概念","03347":"泰格医药","BK1583":"高瓴概念","ADC":"艾格里房产","BK4023":"应用软件","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4080":"零售业房地产投资信托"},"translate_title":"Baili Tianheng (688506. SH): BL-M08D1 (ADC) clinical trial application approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688506":1,"03347":1,"ADC":1,"BL":1},"content_text":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M08D1(ADC)的药物临床试验获得批准。BL-M08D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物，其适应症为复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486396776"}